Colospa - myotropic spasmolytic with selective effect on unstriated muscles of digestive tract. Eliminates a spasm, without influencing a normal peristaltics of intestines. Unlike cholinolytic medicine, Colospa does not affect at muscarinic receptor and does not cause characteristic of antispasmodics with muscarinic receptor action of side effects (feeling of dryness in a mouth, vision disorders, an urination delay) that allows for patients to take it at prostatauxe or glaucoma. Taking of Colospa is not followed by development of reflex hypotonia of intestines.

Anti-migraine drug. Specific and selective agonist of 5-HT1-serotonin receptors, localized predominantly in the blood vessels of the brain and it does not affect other subtypes of 5-HT-serotonin receptors (5-HT2-7). Causes narrowing of the vessels of the carotid arterial bed, that supply extracranial and intracranial tissues with blood (vasodilation of the meninges and / or their edema is the main mechanism of migraine development in humans) without significantly affecting cerebral blood flow.